Financial News

A new batch of data for Gilead Sciences’ remdesivir points to efficacy but it’s no ‘silver bullet’

A slice of data from the third clinical trial for Gilead Sciences Inc.’s remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients but is not the silver bullet that had been hoped for.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback